Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma

INGELHEIM, Germany.-Tuesday 4 February 2020 [ AETOS Wire ]

  • Aservo® EquiHaler® (ciclesonide inhalation solution) is a result of synergies between the company’s human pharma and animal health businesses.
  • The inhaler addresses an unmet need in the equine segment.
  • The company continues to set new standards of care to strengthen its commitment to animal welfare.

(BUSINESS WIRE)-- Horses with severe equine asthma struggle to breath, even at rest. Last week, the European Commission granted marketing authorization1 to Boehringer Ingelheim for the new Aservo® EquiHaler® - and horses that suffer from severe equine asthma can now benefit from this new therapy.

While inhaled therapies for the treatment of asthma are common in human health, the approval of the Aservo® EquiHaler® marks an industry first in equine medicine, as until now, there has been no approved corticosteroid inhalant therapy licensed for use in horses with severe equine asthma.

The Aservo® EquiHaler® represents the culmination of over a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. The Respimat™ inhaler used in human respiratory disease is differentiated by the unique Soft Mist™ Technology, which was integrated into the new Aservo® EquiHaler®, allowing medication to be inhaled, deep into the lung. “The inhaler is a prime example of leveraging innovation efforts of both our businesses. This has been a strength in the past and we will expand this in the near future to further increase the delivery of innovative solutions for our patients and customers,” shares Eric Haaksma, Head of R&D, Boehringer Ingelheim Animal Health Business Unit.

The newly approved inhaler is designed specifically for use in horses. It includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adaptor that fits gently inside the nostril of the horse, allowing the horses to easily inhale the medicated mist. The active ingredient in the Aservo® EquiHaler® is the prodrug ciclesonide, which is a corticosteroid that is activated directly in the lung, reducing lower airway inflammation associated with severe equine asthma.

“Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breath,” says Erich Schoett, Global Business Head of Equine for the Boehringer Ingelheim Animal Health Business Unit. “Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”

The Aservo® EquiHaler® is expected to be available for veterinarians in the EU in 2020.

For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/approval-aservo-equihaler-equine-asthma-therapy

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005437/en/


Contacts

Boehringer Ingelheim
Tereza Urbankova
Head of External Communication Animal Health
Boehringer Ingelheim Corporate Center GmbH
P: +49 6132 77-184817
tereza.urbankova@boehringer-ingelheim.com





Permalink : https://www.aetoswire.com/news/boehringer-ingelheim-receives-approval-for-aservoreg-equihalerreg-industry-first-therapy-for-severe-equine-asthma/en

Permalink : https://www.aetoswire.com/news/boehringer-ingelheim-receives-approval-for-aservoreg-equihalerreg-industry-first-therapy-for-severe-equine-asthma/en